MCID: PDT009
MIFTS: 27

Pediatric Liposarcoma

Categories: Cancer diseases

Aliases & Classifications for Pediatric Liposarcoma

MalaCards integrated aliases for Pediatric Liposarcoma:

Name: Pediatric Liposarcoma 12 15
Childhood Liposarcoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:5695
NCIt 49 C8091
UMLS 71 C0279984

Summaries for Pediatric Liposarcoma

MalaCards based summary : Pediatric Liposarcoma, also known as childhood liposarcoma, is related to retroperitoneal fibrosis and anaplastic ependymoma. An important gene associated with Pediatric Liposarcoma is MDM2 (MDM2 Proto-Oncogene), and among its related pathways/superpathways are MicroRNAs in cancer and DNA Damage. The drugs Ifosfamide and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include bone, and related phenotypes are Reduced mammosphere formation and neoplasm

Related Diseases for Pediatric Liposarcoma

Diseases related to Pediatric Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 115)
# Related Disease Score Top Affiliating Genes
1 retroperitoneal fibrosis 10.2 VIM MDM2
2 anaplastic ependymoma 10.2 VIM MDM2
3 melanotic neuroectodermal tumor 10.2 VIM MDM2
4 ring chromosome 7 10.2 MDM2 CDK4
5 mediastinum liposarcoma 10.2 MDM2 CDK4
6 hereditary melanoma 10.2 MDM2 CDK4
7 undifferentiated embryonal sarcoma of the liver 10.2 MDM2 CDK4
8 lipoblastoma 10.2 MDM2 CDK4
9 diffuse lipomatosis 10.2 MDM2 CDK4
10 malignant inflammatory fibrous histiocytoma 10.2 MDM2 CDK4
11 adult liposarcoma 10.2 MDM2 CDK4
12 juxtacortical osteosarcoma 10.2 MDM2 CDK4
13 paratesticular lipoma 10.1 MDM2 CDK4
14 lipoma of spermatic cord 10.1 MDM2 CDK4
15 peripheral osteosarcoma 10.1 MDM2 CDK4
16 parameningeal embryonal rhabdomyosarcoma 10.1 MDM2 CDK4
17 embryonal rhabdomyosarcoma 10.1 MDM2 CDK4
18 myositis ossificans 10.1 MDM2 CDK4
19 familial retinoblastoma 10.1 MDM2 CDK4
20 epithelial-myoepithelial carcinoma 10.1 VIM HMGA2
21 myoepithelial carcinoma 10.1 VIM HMGA2
22 benign ependymoma 10.1 VIM MDM2
23 conventional central osteosarcoma 10.1 MDM2 CDK4
24 bone osteosarcoma 10.1 MDM2 CDK4
25 extraskeletal ewing sarcoma 10.0 VIM FUS
26 aortic malignant tumor 9.9 MDM2 CD34
27 inflammatory liposarcoma 9.9 MDM2 CD34
28 heart sarcoma 9.9 MDM2 CD34
29 malignant mesenchymoma 9.9 MDM2 CD34
30 glomangiomyoma 9.9 VIM CD34
31 pleomorphic adenoma 9.9 VIM MDM2 HMGA2
32 conventional fibrosarcoma 9.9 MDM2 CD34
33 glomangioma 9.9 VIM CD34
34 adenoid squamous cell carcinoma 9.9 VIM CD34
35 embryonal sarcoma 9.9 VIM MDM2 CDK4
36 vaginal endometrial stromal sarcoma 9.9 VIM CD34
37 atypical teratoid rhabdoid tumor 9.9 VIM HMGA2
38 heart cancer 9.9 MDM2 CD34
39 central epithelioid sarcoma 9.9 VIM CD34
40 chondrosarcoma 9.9 VIM MDM2 CDK4
41 epithelioid sarcoma 9.9 VIM CD34
42 intravenous leiomyomatosis 9.9 HMGA2 CD34
43 vulvar proximal-type epithelioid sarcoma 9.9 VIM CD34
44 chondroid lipoma 9.9 HMGA2 CD34
45 vagina sarcoma 9.9 VIM CD34
46 vulvar leiomyoma 9.9 HMGA2 CD34
47 fibrous meningioma 9.9 VIM CD34
48 clear cell meningioma 9.8 VIM CD34
49 monophasic synovial sarcoma 9.8 VIM CD34
50 ring chromosome 9.8 MDM2 HMGA2 CDK4

Graphical network of the top 20 diseases related to Pediatric Liposarcoma:



Diseases related to Pediatric Liposarcoma

Symptoms & Phenotypes for Pediatric Liposarcoma

GenomeRNAi Phenotypes related to Pediatric Liposarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.02 CD34 CDK4 DDIT3 MDM2 VIM

MGI Mouse Phenotypes related to Pediatric Liposarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 8.92 CD34 CDK4 DDIT3 MDM2

Drugs & Therapeutics for Pediatric Liposarcoma

Drugs for Pediatric Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ifosfamide Approved Phase 3 3778-73-2 3690
2
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
3
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
4
Etoposide Approved Phase 3 33419-42-0 36462
5
Epirubicin Approved Phase 3 56420-45-2 41867
6
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
7
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
8
Histamine Approved, Investigational Phase 3 51-45-6 774
9
Cyproheptadine Approved Phase 3 129-03-3 2913
10 Immunologic Factors Phase 3
11 Antirheumatic Agents Phase 3
12 Alkylating Agents Phase 3
13
Isophosphamide mustard Phase 3 0
14 Anti-Bacterial Agents Phase 3
15 Antibiotics, Antitubercular Phase 3
16 Etoposide phosphate Phase 3
17 Immunosuppressive Agents Phase 3
18 Anti-Infective Agents Phase 3
19 Tubulin Modulators Phase 3
20 Antimitotic Agents Phase 3
21 Neurotransmitter Agents Phase 3
22 Histamine Antagonists Phase 3
23 Anti-Allergic Agents Phase 3
24
Histamine Phosphate Phase 3 51-74-1 65513
25 Histamine H1 Antagonists Phase 3
26 Dermatologic Agents Phase 3
27 Gastrointestinal Agents Phase 3
28
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
29
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
30
Lenograstim Approved, Investigational Phase 2 135968-09-1
31 Protein Kinase Inhibitors Phase 2
32 Imatinib Mesylate Phase 2 220127-57-1 123596
33
Liposomal doxorubicin Phase 2 31703
34
Sargramostim Approved, Investigational Phase 1 83869-56-1, 123774-72-1
35
Celecoxib Approved, Investigational Phase 1 169590-42-5 2662
36 Molgramostim Investigational Phase 1 99283-10-0
37 Vaccines Phase 1
38 Cyclooxygenase 2 Inhibitors Phase 1
39 Analgesics Phase 1
40 Analgesics, Non-Narcotic Phase 1
41 Anti-Inflammatory Agents Phase 1
42 Cyclooxygenase Inhibitors Phase 1
43 Anti-Inflammatory Agents, Non-Steroidal Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
3 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
4 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
5 MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
6 A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF Completed NCT00069940 Phase 1
7 A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity Completed NCT00450736 Phase 1 celecoxib
8 Prevention of Mucositis in Children With AES-14 (IND#36978), a Glutamine Based Oral Care Regimen, for Patients Diagnosed With Solid Tumors: A Randomized Placebo-Controlled Clinical Study Withdrawn NCT00334984 glutamine

Search NIH Clinical Center for Pediatric Liposarcoma

Genetic Tests for Pediatric Liposarcoma

Anatomical Context for Pediatric Liposarcoma

MalaCards organs/tissues related to Pediatric Liposarcoma:

40
Bone

Publications for Pediatric Liposarcoma

Articles related to Pediatric Liposarcoma:

# Title Authors PMID Year
1
Prognostic factors and survival in pediatric and adolescent liposarcoma. 61
22991488 2012
2
Liposarcoma in children and young adults: a multi-institutional experience. 61
21394894 2011
3
Childhood liposarcoma: a single-institutional twenty-year experience. 61
10505317 1999
4
[Childhood liposarcoma. Diagnostic problems]. 61
3377348 1988
5
[Childhood liposarcoma of the eyelid--a case report]. 61
3723810 1986
6
Childhood liposarcoma. Report of a case and review of the literature. 61
6733687 1984

Variations for Pediatric Liposarcoma

Expression for Pediatric Liposarcoma

Search GEO for disease gene expression data for Pediatric Liposarcoma.

Pathways for Pediatric Liposarcoma

Pathways related to Pediatric Liposarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.92 VIM MDM2 HMGA2
2 11.8 VIM MDM2 CDK4
3 11.21 MDM2 HMGA2 FUS DDIT3
4 11.14 DDIT3 CDK4
5 11.03 MDM2 CDK4
6 10.97 MDM2 CDK4
7 10.46 MDM2 CDK4

GO Terms for Pediatric Liposarcoma

Cellular components related to Pediatric Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-DNA complex GO:0032993 8.96 HMGA2 DDIT3
2 polysome GO:0005844 8.62 VIM FUS

Biological processes related to Pediatric Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron projection development GO:0010977 9.32 VIM MDM2
2 positive regulation of cell cycle GO:0045787 9.26 MDM2 CDK4
3 negative regulation of DNA binding GO:0043392 9.16 HMGA2 DDIT3
4 negative regulation of cell cycle arrest GO:0071157 8.96 MDM2 CDK4
5 positive regulation of gene expression GO:0010628 8.92 VIM MDM2 HMGA2 CD34

Molecular functions related to Pediatric Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 scaffold protein binding GO:0097110 8.96 VIM MDM2
2 transcription factor binding GO:0008134 8.8 HMGA2 DDIT3 CD34

Sources for Pediatric Liposarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....